Immunic Price To Sales Ratio vs Capex To Depreciation Analysis

IMUX Stock  USD 1.13  0.08  6.61%   
Immunic financial indicator trend analysis is infinitely more than just investigating Immunic recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Immunic is a good investment. Please check the relationship between Immunic Price To Sales Ratio and its Capex To Depreciation accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunic. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
For more information on how to buy Immunic Stock please use our How to Invest in Immunic guide.

Price To Sales Ratio vs Capex To Depreciation

Price To Sales Ratio vs Capex To Depreciation Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Immunic Price To Sales Ratio account and Capex To Depreciation. At this time, the significance of the direction appears to have strong contrarian relationship.
The correlation between Immunic's Price To Sales Ratio and Capex To Depreciation is -0.58. Overlapping area represents the amount of variation of Price To Sales Ratio that can explain the historical movement of Capex To Depreciation in the same time period over historical financial statements of Immunic, assuming nothing else is changed. The correlation between historical values of Immunic's Price To Sales Ratio and Capex To Depreciation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Price To Sales Ratio of Immunic are associated (or correlated) with its Capex To Depreciation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capex To Depreciation has no effect on the direction of Price To Sales Ratio i.e., Immunic's Price To Sales Ratio and Capex To Depreciation go up and down completely randomly.

Correlation Coefficient

-0.58
Relationship DirectionNegative 
Relationship StrengthVery Weak

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Immunic stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Immunic sales, a figure that is much harder to manipulate than other Immunic multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Capex To Depreciation

The ratio of a company's capital expenditures to its depreciation expenses, indicating how much the company is investing in physical assets relative to the aging of existing assets.
Most indicators from Immunic's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Immunic current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunic. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
For more information on how to buy Immunic Stock please use our How to Invest in Immunic guide.Selling General Administrative is likely to drop to about 14 M in 2024. Issuance Of Capital Stock is likely to drop to about 810.4 K in 2024
 2021 2022 2023 2024 (projected)
Net Interest Income66K1.0M3.1M3.2M
Interest Income66K1.0M3.1M3.2M

Immunic fundamental ratios Correlations

0.310.320.390.960.21-0.95-0.040.570.960.60.960.41-0.620.70.33-0.530.210.97-0.23-0.48-0.530.280.280.340.05
0.310.620.690.21-0.04-0.31-0.580.20.34-0.160.370.82-0.220.40.560.05-0.040.39-0.030.06-0.450.560.560.47-0.51
0.320.620.970.220.23-0.33-0.620.430.4-0.190.390.82-0.450.320.46-0.090.230.4-0.2-0.43-0.470.640.650.3-0.57
0.390.690.970.270.09-0.34-0.60.390.410.00.40.91-0.460.420.45-0.080.090.42-0.07-0.42-0.560.570.580.31-0.46
0.960.210.220.270.28-0.94-0.040.550.930.590.920.26-0.750.640.38-0.730.280.93-0.14-0.6-0.550.330.320.180.03
0.21-0.040.230.090.28-0.430.060.670.42-0.380.41-0.19-0.34-0.150.04-0.351.00.37-0.58-0.320.240.190.190.17-0.11
-0.95-0.31-0.33-0.34-0.94-0.430.03-0.68-0.99-0.39-0.99-0.290.63-0.55-0.340.56-0.43-0.980.340.490.44-0.36-0.36-0.360.05
-0.04-0.58-0.62-0.6-0.040.060.030.13-0.070.24-0.07-0.640.4-0.23-0.880.190.06-0.09-0.150.30.64-0.83-0.840.120.86
0.570.20.430.390.550.67-0.680.130.690.030.670.21-0.440.2-0.03-0.330.670.65-0.33-0.41-0.180.240.240.30.01
0.960.340.40.410.930.42-0.99-0.070.690.380.990.36-0.640.550.35-0.540.420.99-0.34-0.5-0.470.380.380.36-0.08
0.6-0.16-0.190.00.59-0.38-0.390.240.030.380.350.12-0.270.570.02-0.3-0.380.390.27-0.33-0.43-0.19-0.2-0.030.53
0.960.370.390.40.920.41-0.99-0.070.670.990.350.37-0.630.560.35-0.530.411.0-0.36-0.44-0.450.370.370.38-0.09
0.410.820.820.910.26-0.19-0.29-0.640.210.360.120.37-0.330.580.530.03-0.190.40.03-0.2-0.620.510.520.39-0.43
-0.62-0.22-0.45-0.46-0.75-0.340.630.4-0.44-0.64-0.27-0.63-0.33-0.38-0.550.92-0.34-0.63-0.120.870.67-0.56-0.570.20.32
0.70.40.320.420.64-0.15-0.55-0.230.20.550.570.560.58-0.380.44-0.25-0.150.63-0.09-0.26-0.50.310.310.34-0.11
0.330.560.460.450.380.04-0.34-0.88-0.030.350.020.350.53-0.550.44-0.420.040.380.04-0.39-0.70.860.860.0-0.73
-0.530.05-0.09-0.08-0.73-0.350.560.19-0.33-0.54-0.3-0.530.030.92-0.25-0.42-0.35-0.52-0.160.790.51-0.39-0.380.360.16
0.21-0.040.230.090.281.0-0.430.060.670.42-0.380.41-0.19-0.34-0.150.04-0.350.37-0.58-0.320.240.190.190.17-0.11
0.970.390.40.420.930.37-0.98-0.090.650.990.391.00.4-0.630.630.38-0.520.37-0.35-0.45-0.470.370.380.4-0.09
-0.23-0.03-0.2-0.07-0.14-0.580.34-0.15-0.33-0.340.27-0.360.03-0.12-0.090.04-0.16-0.58-0.35-0.17-0.430.050.06-0.68-0.04
-0.480.06-0.43-0.42-0.6-0.320.490.3-0.41-0.5-0.33-0.44-0.20.87-0.26-0.390.79-0.32-0.45-0.170.59-0.45-0.450.30.18
-0.53-0.45-0.47-0.56-0.550.240.440.64-0.18-0.47-0.43-0.45-0.620.67-0.5-0.70.510.24-0.47-0.430.59-0.68-0.690.240.45
0.280.560.640.570.330.19-0.36-0.830.240.38-0.190.370.51-0.560.310.86-0.390.190.370.05-0.45-0.681.0-0.08-0.87
0.280.560.650.580.320.19-0.36-0.840.240.38-0.20.370.52-0.570.310.86-0.380.190.380.06-0.45-0.691.0-0.08-0.87
0.340.470.30.310.180.17-0.360.120.30.36-0.030.380.390.20.340.00.360.170.4-0.680.30.24-0.08-0.080.15
0.05-0.51-0.57-0.460.03-0.110.050.860.01-0.080.53-0.09-0.430.32-0.11-0.730.16-0.11-0.09-0.040.180.45-0.87-0.870.15
Click cells to compare fundamentals

Immunic Account Relationship Matchups

Immunic fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets66.0M167.9M139.1M127.8M54.3M81.3M
Other Current Liab343K4.4M7.2M8.2M18.9M19.9M
Total Current Liabilities7.1M8.4M11.4M13.1M24.7M26.0M
Total Stockholder Equity58.4M158.8M127.1M113.7M28.9M27.5M
Property Plant And Equipment Net713K1.1M1.1M1.8M1.8M1.4M
Net Debt(28.8M)(126.8M)(86.3M)(105.2M)(45.3M)(47.6M)
Retained Earnings(59.9M)(103.9M)(196.9M)(317.3M)(410.9M)(390.3M)
Accounts Payable2.4M3.7M3.7M4.3M5.1M3.9M
Cash29.4M127.5M86.9M106.7M46.7M64.0M
Non Current Assets Total33.7M34.1M34.1M1.9M1.8M1.7M
Cash And Short Term Investments29.4M127.5M86.9M116.4M46.7M66.0M
Common Stock Shares Outstanding7.7M15.7M23.7M31.8M44.3M46.5M
Liabilities And Stockholders Equity66.0M167.9M139.1M127.8M54.3M81.3M
Non Current Liabilities Total520K679K584K992K639K607.1K
Other Current Assets2.9M6.3M18.1M9.5M5.9M4.6M
Other Stockholder Equity53.7M266.8M324.2M427.9M436.1M245.3M
Total Liab7.6M9.1M12.0M14.1M25.4M26.6M
Property Plant And Equipment Gross713K1.1M1.1M1.8M1.8M1.4M
Total Current Assets32.2M133.7M105.0M125.9M52.5M70.8M
Accumulated Other Comprehensive Income(1.4M)(4.1M)(252K)3.0M3.8M3.9M
Non Currrent Assets Other108K37K42K43K38.7K36.8K
Net Tangible Assets25.4M125.8M94.1M113.7M130.7M80.6M
Retained Earnings Total Equity(59.9M)(103.9M)(196.9M)(317.3M)(285.6M)(299.8M)
Capital Surpluse119.6M266.8M324.2M427.9M492.1M326.3M
Non Current Liabilities Other520K679K584K992K1.1M1.2M
Property Plant Equipment80K203K1.1M294K264.6K251.4K
Other Assets37K42K943K43K49.5K47.0K
Net Receivables408K1.6M2.2M2.7M703K1.3M
Net Invested Capital58.4M158.8M127.1M113.7M28.9M27.5M
Net Working Capital25.2M125.3M93.6M112.8M27.8M26.4M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Immunic Stock Analysis

When running Immunic's price analysis, check to measure Immunic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunic is operating at the current time. Most of Immunic's value examination focuses on studying past and present price action to predict the probability of Immunic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunic's price. Additionally, you may evaluate how the addition of Immunic to your portfolios can decrease your overall portfolio volatility.